3-(2-Chlorophenyl)-5-ethoxy-1,3-dihydroindol-2-one | 169040-57-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(2-Chlorophenyl)-5-ethoxy-1,3-dihydroindol-2-one
• CAS: 169040-57-7
• 化学式: C₁₆H₁₄ClNO₂
• 分子量: 287.746
• InChiKey: BTCYFJXKJPQILU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-4-ethoxyphenyl-DL-2-chloromandelamide 生成 3-Amino-5-chloro-3-(2-chlorophenyl)-1,3-di-hydroindol-2-one 、 3-(2-Chlorophenyl)-5-ethoxy-1,3-dihydroindol-2-one
  参考文献：
  名称：

  1,3-dihydroindol-2-one derivatives substituted in the 3-position by a

  摘要：

  本发明涉及式(I)化合物及其盐，如适用：这些化合物具有对加压素和/或催产素受体的亲和力。

  公开号：

  US05594023A1

文献信息

• Indol-2-one derivatives
  申请人：Sanofi

  公开号：US05773612A1

  公开（公告）日：1998-06-30

  A compound of formula II' ##STR1## in which R.sub.I is an ethoxy group or a chlorine atom; R.sub.II is hydrogen, a chlorine atom or a methyl group; R.sub.III is a chlorophenyl group or a methoxyphenyl group; R.sub.IV is an amino group, a group NR.sub.9 R.sub.10 or NR.sub.9 R.sub.XI, or a piperazin-1-yl radical substituted in the 4-position by a (C.sub.2 -C.sub.10)alkylene group substituted by an amino group which is free or carries a protective group; R.sub.10 is (CH.sub.2).sub.p R.sub.35 or a (C.sub.2 -C.sub.10)alkylene group substituted by R.sub.21 ; R.sub.XI is a (C.sub.1 -C.sub.12)alkyl group or a group .omega.-R.sub.32 R.sub.33 N(C.sub.1 -C.sub.4)-alkylcarbonyl; and R.sub.21 is R.sub.36 ; a group OR.sub.37 ; a group NR.sub.32 R.sub.33 ; a cyano group; a group S(C.sub.1 -C.sub.7)alkyl; a group SO(C.sub.1 -C.sub.7)alkyl; or a group SO.sub.2 (C.sub.1 -C.sub.7)alkyl; R.sub.35 is a piperid-4-yl group which is unsubstituted or substituted in the 1-position by a (C.sub.1 -C.sub.7)alkoxycarbonyl group or by a (C.sub.1 -C.sub.7)alkyl group; or a pyrid-2-yl group; R.sub.37 is R.sub.13 ; a (C.sub.3 -C.sub.7)cycloalkyl group; a (C.sub.1 -C.sub.6)alkylene group substituted by R.sub.24 ; a (C.sub.2 -C.sub.6)alkylene group substituted by a hydroxyl or a (C.sub.1 -C.sub.7)alkoxy group; or a (C.sub.2 -C.sub.6)alkylene group substituted by an amino group which is free or substituted by one or two (C.sub.1 -C.sub.7)alkyl groups or by a protective group; R.sub.24 is a carboxyl group; a (C.sub.1 -C.sub.7)alkoxycarbonyl group; a benzyloxycarbonyl group; or a carbamoyl group which is free or substituted by one or two (C.sub.1 -C.sub.7)alkyl groups.

  化合物II'的化学式为##STR1## 其中R.sub.I为乙氧基或氯原子；R.sub.II为氢、氯原子或甲基基团；R.sub.III为氯苯基或甲氧基苯基；R.sub.IV为氨基、NR.sub.9 R.sub.10或NR.sub.9 R.sub.XI基团，或者在4-位置被取代的哌嗪-1-基基团，所取代的基团为(C.sub.2 -C.sub.10)烷基基团，该基团被氨基自由取代或带有保护基；R.sub.10为(CH.sub.2).sub.p R.sub.35或(C.sub.2 -C.sub.10)烷基基团，该基团被R.sub.21取代；R.sub.XI为(C.sub.1 -C.sub.12)烷基基团或.omega.-R.sub.32 R.sub.33 N(C.sub.1 -C.sub.4)-烷基羰基基团；R.sub.21为R.sub.36、OR.sub.37、NR.sub.32 R.sub.33、氰基、S(C.sub.1 -C.sub.7)烷基、SO(C.sub.1 -C.sub.7)烷基或SO.sub.2 (C.sub.1 -C.sub.7)烷基；R.sub.35为哌啶-4-基基团，该基团未取代或在1-位置被(C.sub.1 -C.sub.7)烷氧羰基基团或(C.sub.1 -C.sub.7)烷基基团取代；或者为吡啶-2-基基团；R.sub.37为R.sub.13、(C.sub.3 -C.sub.7)环烷基团、被R.sub.24取代的(C.sub.1 -C.sub.6)烷基基团、被羟基或(C.sub.1 -C.sub.7)烷氧基取代的(C.sub.2 -C.sub.6)烷基基团；或者被自由氨基或被一或两个(C.sub.1 -C.sub.7)烷基或保护基取代的(C.sub.2 -C.sub.6)烷基基团；R.sub.24为羧基、(C.sub.1 -C.sub.7)烷氧羰基、苄氧羰基或自由或被一或两个(C.sub.1 -C.sub.7)烷基取代的氨基基团。
• DERIVES DE 1,3-DIHYDROINDOL-2-ONE SUBSTITUES EN 3 PAR UN GROUPE AZOTE COMME AGONISTES ET/OU ANTAGONISTES DE LA VASOPRESSINE ET/OU DE L'OCYTOCINE
  申请人：SANOFI

  公开号：EP0687251A1

  公开（公告）日：1995-12-20
• US5594023A
  申请人：——

  公开号：US5594023A

  公开（公告）日：1997-01-14
• US5773612A
  申请人：——

  公开号：US5773612A

  公开（公告）日：1998-06-30
• [EN] 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS<br/>[FR] DERIVES DE 1,3-DIHYDROINDOL-2-ONE SUBSTITUES EN 3 PAR UN GROUPE AZOTE COMME AGONISTES ET/OU ANTAGONISTES DE LA VASOPRESSINE ET/OU DE L'OCYTOCINE
  申请人：SANOFI

  公开号：WO1995018105A1

  公开（公告）日：1995-07-06

  (EN) Compounds of formula (I), wherein R1 and R2 are each independently hydrogen, halogen, (C1-C7)alkyl, (C1-C7)alkoxy, trifluoromethyl; R3 is (C1-C7)alkyl, (C3-C7)cycloalkyl; cyclohexyl, cyclohexylmethyl, phenyl, benzyl; R4 is azido, a 2,2-dimethylhydrazino group; (C1-C7)alkylsulfonamido; phenylsulfonamido, dimethylaminosulfonamido, a NR7R8 group; a NR9R10 group; a NR9R11 group; a R12 heterocyclic radical, piperazin-1-yl; a lactoylamino group, a mandeloylamino group; a N'-(1-phenylethyl)ureido group; a N'-(1-naphth-1-ylethyl)ureido group; R5 is hydrogen or one of the values assigned to R6; R6 is halogen; (C1-C7)alkyl, trifluoromethyl, cyano, aminomethyl, nitro, an NR9R11 group; a heterocyclic radical selected from pyrrol-1-yl, $g(D)3-pyrrolin-1-yl, pyrrolidin-1-yl, morpholin-4-yl; an OR13 group; a SR13 group; guanidino, formyl, (C1-C7)alkylcarbonyl, carbamoyl; thiocarbamoyl, sulfamoyl, carboxy, (C1-C7)alkoxycarbonyl; phenoxycarbonyl, benzyloxycarbonyl, (C1-C7)alkylsulfonamido, phenylsulfonamido, dimethylaminosulfonamido, 2-(4methylphenyl)benzamido; or R5 and R6 together with the phenyl to which they are attached form a group (a); provided that X is -SO2-; X is SO2; CH2. The compounds of the invention have an affinity for vasopressin and/or ocytocine receptors.(FR) La présente invention a pour objet des composés de formule (I), dans laquelle R1 et R2 représentent chacun indépendamment un hydrogène; un halogène; un (C1-C7)alkyle; un (C1-C7)alcoxy; un trifluorométhyle; R3 représente un (C1-C7)alkyle; un (C3-C7)cycloalkyle; un cyclohexyle; un cyclohexylméthyle; un phényle; un benzyle; R4 représente un azido; un groupe 2,2-diméthylhydrazino; un (C1-C7)alkylsulfonamido; un phénylsulfonamido; un diméthylaminosulfonamido; un groupe NR7R8; un groupe NR9R10; un groupe NR9R11; un radical hétérocyclique R12; un pipérazin-1-yle; un groupe lactoylamino; un groupe mandéloylamino; un groupe N'-(1-phényléthyl)uréido; un groupe N'-(1-napht-1-yléthyl)uréido; R5 représente l'hydrogène ou l'une des valeurs désignées pour R6; R6 représente un halogène; un (C1-C7)alkyle; un trifluorométhyle; un cyano; un aminométhyle; un nitro; un groupe NR9R11; un radical hétérocyclique choisi parmi le pyrrol-1-yle, le $g(D)3-pyrrolin-1-yle, la pyrrolidin-1-yle, la morpholin-4-yle; un groupe OR13; un groupe SR13; un guanidino; un formyle; un (C1-C7)alkylcarbonyle; un carbamoyle; un thiocarbamoyle; un sulfamoyle; un carboxy; un (C1-C7)alcoxycarbonyle; un phénoxycarbonyle; un benzyloxycarbonyle; un (C1-C7)alkylsulfonamido; un phénylsulfonamido; un diméthylaminosulfonamido; un 2-(4-méthylphényl)benzamido; ou R5 et R6 ensemble avec le phényle auquel ils sont liés constituent un groupe (a) à la condition que X soit -SO2-; X représente SO2; CH2. Ces composés ont une affinité pour les récepteurs de la vasopressine et/ou de l'ocytocine.